Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by low numbers of platelets, leading to bruising and an increased risk of bleeding. It is estimated that up to 100 per million people live with ITP, and the disorder is considered chronic when symptoms last more than 12 months. Currently, no cure is available, and these patients have usually relapsed after various treatments, yet still require treatment to reduce the risk of clinically significant bleeding.
Om Doptelet® (avatrombopag)
Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by both the
About immune thrombocytopenia (ITP)
Immune thrombocytopenia is an autoimmune disorder characterised by low numbers of platelets, leading to bruising and an increased risk of bleeding. The incidence of primary ITP in adults is 3.3 per 100 000 adults per year with a prevalence of 9.5 per 100 000 adults[1]. The disorder is considered chronic when symptoms last more than 12 months. There is no cure for these patients, they have usually relapsed after various treatments, and does still require treatment to reduce the risk of clinically significant bleeding.
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across
Sobi
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
[1] (Lambert et al. Blood 2017)
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/doptelet---avatrombopag--receives-positive-opinion-from-chmp-for-treatment-of-itp,c3253249
https://mb.cision.com/Main/14266/3253249/1347365.pdf
(c) 2020 Cision. All rights reserved., source